Merck's Melanoma Breakthrough Boosts Stock Amid Patent Concerns

Merck's recent Phase 3 study of intismeran autogene with Keytruda has met its primary endpoints in melanoma, marking a significant milestone for the company. This validation of clinical benefits comes as investors are reassessing the stock's long-term opportunity.

The study's success is reflected in Merck's share price, which has seen a 30-day return of 17.08% and a 90-day return of 27.70%, contributing to a 1-year total shareholder return of 88.20%. This growth has investors looking at the company's oncology pipeline and patent risks more closely.

Despite trading slightly above the average analyst target, Merck still screens as a sizeable discount to some intrinsic value estimates. The most followed narrative on Merck points to a fair value of $136.85, implying a premium in the current share price.